Vor Biopharma Inc. Announces Board and Executive Changes

Ticker: VOR · Form: 8-K · Filed: May 20, 2025 · CIK: 1817229

Vor Biopharma Inc. 8-K Filing Summary
FieldDetail
CompanyVor Biopharma Inc. (VOR)
Form Type8-K
Filed DateMay 20, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-of-directors, executive-compensation

TL;DR

Vor Bio board shakeup & comp changes filed. Big moves ahead?

AI Summary

Vor Biopharma Inc. announced on May 19, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. Specific details regarding the individuals involved and the exact nature of the compensation changes are outlined within the report.

Why It Matters

Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial health, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in leadership and compensation can indicate internal shifts that may affect the company's strategic direction and operational stability.

Key Numbers

  • 001-39979 — SEC File Number (Identifies the company's filing history with the SEC.)
  • 0001817229 — Central Index Key (Unique identifier for the filer in the SEC EDGAR system.)

Key Players & Entities

  • Vor Biopharma Inc. (company) — Registrant
  • May 19, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140 (address) — Principal Executive Offices
  • (617) 655-6580 (phone_number) — Registrant's telephone number

FAQ

What specific roles have been affected by the departure of officers or directors?

The filing indicates the departure of certain officers and directors, but the specific roles are detailed within the full report, not summarized in this excerpt.

Who are the newly elected directors?

The filing states that new directors have been elected, but their names are not provided in this summary section.

What are the key changes in compensatory arrangements for officers?

The report mentions updates to compensatory arrangements for certain officers, with specific details to be found in the full document.

What is the effective date of these reported changes?

The earliest event reported is dated May 19, 2025.

Where are Vor Biopharma Inc.'s principal executive offices located?

Vor Biopharma Inc.'s principal executive offices are located at 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 20, 2025 regarding Vor Biopharma Inc. (VOR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.